← All trials
NCT04794088
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Feb 28, 2022
- First posted
- Mar 11, 2021
- Last posted
- Mar 24, 2021
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Free University of AmsterdamLead sponsor
- Free University of AmsterdamSponsor investigator
- Exvastat Ltd.Collaborator
- Free University of AmsterdamStudy director
- Simbec-OrionCollaborator
- KABS laboratoriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.